Mangoceuticals, Inc. (MGRX) stock
MGRXNasdaqServices-Misc Health & Allied Services, NECFiscal year ends December 31
$0.13−0.01 (-8.74%)
Close on Nov 19, 2026Market cap $2.88MP/E –Yield –
Mangoceuticals gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Mangoceuticals's gross profit for the twelve months ending Jun 30, 2026 was $171.59K, down 45.5% year over year. For fiscal 2025 it was $250.39K, down 34.1% from the year before.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $250.39K | -34.1% |
| FY2024 | Dec 31, 2024 | $379.96K | -11.9% |
| FY2023 | Dec 31, 2023 | $431.50K | +8796.9% |
| FY2022 | Dec 31, 2022 | $4.85K | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $44.22K | -50.8% |
| Q1 FY2026 | Mar 31, 2026 | $29.00K | -53.3% |
| Q4 FY2025 | Dec 31, 2025 | $47.48K | -40.7% |
| Q3 FY2025 | Sep 30, 2025 | $50.90K | -38.4% |
| Q2 FY2025 | Jun 30, 2025 | $89.95K | +28.9% |
| Q1 FY2025 | Mar 31, 2025 | $62.06K | -57.9% |
| Q4 FY2024 | Dec 31, 2024 | $80.10K | -43.8% |
| Q3 FY2024 | Sep 30, 2024 | $82.67K | -42.8% |
| Q2 FY2024 | Jun 30, 2024 | $69.79K | -19.9% |
| Q1 FY2024 | Mar 31, 2024 | $147.40K | +157.7% |
| Q4 FY2023 | Dec 31, 2023 | $142.58K | – |
| Q3 FY2023 | Sep 30, 2023 | $144.59K | – |
| Q2 FY2023 | Jun 30, 2023 | $87.13K | – |
| Q1 FY2023 | Mar 31, 2023 | $57.20K | – |
See a number that looks wrong?